Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928380 | 1.00 | ALDH1A1 (0.50) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL30377710 | 0.83 | ALDH1A1 (0.53) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL9340887 | 0.83 | ALDH1A1 (0.53) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL4482770 | 0.83 | ALDH1A1 (0.53) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL14020474 | 0.82 | KMT2A (0.48) | ALDH1A1KMT2ACASP3MAPK1 | |
| SCHEMBL14923460 | 0.81 | ELANE (0.49) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL28882530 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2ACASP3CA12CA9 | |
| SCHEMBL14908842 | 0.81 | ELANE (0.49) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL14908843 | 0.81 | ELANE (0.49) | ALDH1A1ELANEKMT2ACASP3CA12 | |
| SCHEMBL14928693 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KMT2ACASP3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885ELANE 1661/4885KMT2A 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.